Literature DB >> 36127596

Multiplex Lysosomal Enzyme Activity Assay on Dried Blood Spots Using Tandem Mass Spectrometry.

Hsuan-Chieh Joyce Liao1, Hsiao-Jan Chen2.   

Abstract

Deficiencies of the enzymes in lysosomes result in the accumulation of undegraded materials and subsequently cellular dysfunction. Early identification of deficiencies can lead to better clinical outcomes before irreversible organ and tissue damages occur. In this chapter, lysosomal enzymes are extracted from dried blood spots and incubated with the commercialized and multiplexed enzyme cocktail containing corresponding substrates and internal standards. After incubation, the enzymatic reactions are quenched, and the mixtures of the reaction products are prepared using liquid/liquid extractions. Multiple enzymes are quantified simultaneously using selected ion monitoring on liquid chromatography-mass spectrometry (LC-MS/MS) system.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Dried blood spot; Enzyme activity assay; Liquid chromatography–mass spectrometry; Lysosomal storage disorders; Newborn screening

Mesh:

Substances:

Year:  2022        PMID: 36127596     DOI: 10.1007/978-1-0716-2565-1_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  Fabry disease: enzymatic diagnosis in dried blood spots on filter paper.

Authors:  N A Chamoles; M Blanco; D Gaggioli
Journal:  Clin Chim Acta       Date:  2001-06       Impact factor: 3.786

2.  Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.

Authors:  Néstor A Chamoles; Gabriela Niizawa; Mariana Blanco; Daniela Gaggioli; Carina Casentini
Journal:  Clin Chim Acta       Date:  2004-09       Impact factor: 3.786

3.  Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.

Authors:  Maria L Escolar; Michele D Poe; James M Provenzale; Karen C Richards; June Allison; Susan Wood; David A Wenger; Daniel Pietryga; Donna Wall; Martin Champagne; Richard Morse; William Krivit; Joanne Kurtzberg
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

4.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

5.  Treatment of Lysosomal Storage Disorders (LSDs).

Authors:  Antonino Tuttolomondo
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

6.  Pompe disease in infants: improving the prognosis by newborn screening and early treatment.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Beth L Thurberg; Shu-Chuan Chiang; Xiaokui Kate Zhang; Joan Keutzer; Ai-Chu Huang; Mei-Hwan Wu; Pei-Hsin Huang; Fuu-Jen Tsai; Yuan-Tsong Chen; Wuh-Liang Hwu
Journal:  Pediatrics       Date:  2009-12       Impact factor: 7.124

Review 7.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

Review 8.  Fabry's disease.

Authors:  Yuri A Zarate; Robert J Hopkin
Journal:  Lancet       Date:  2008-10-18       Impact factor: 79.321

9.  Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.

Authors:  Yin-Hsiu Chien; Shu-Chuan Chiang; Xiaokui Kate Zhang; Joan Keutzer; Ni-Chung Lee; Ai-Chu Huang; Chun-An Chen; Mei-Hwan Wu; Pei-Hsin Huang; Fu-Jen Tsai; Yuan-Tsong Chen; Wuh-Liang Hwu
Journal:  Pediatrics       Date:  2008-06-02       Impact factor: 7.124

10.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.